To evaluate symptom-sign discordance in dry eye disease (DED) using 3 distinct analytical frameworks in a large prospective cohort and to identify associated systemic risk factors. Secondary analysis of a multicenter randomized clinical trial. A total of 535 participants enrolled in the Dry Eye Assessment and Management (DREAM) study with moderate to severe DED. Discordance was assessed at baseline using 3 approaches: (1) a rank-based comparison of symptom-sign severity; (2) a discomfort-based classification using Brief Ocular Discomfort Inventory (BODI) questionnaire; and (3) a novel temporal method evaluating symptom-sign changes between months 3 and 12. Patients were categorized as concordant, symptom-dominant, or sign-dominant discordant using each method. Multivariable regression models were used to identify predictors of discordance. Prevalence and characteristics of symptom-sign discordance across methods; strength of associations between symptoms, discomfort, and clinical signs; and clinical and systemic predictors of discordance. Using the rank-based method, 77% of patients were discordant. Symptom-dominant discordance (37.8%) was associated with younger age and greater ocular discomfort, while sign-dominant discordance (39.3%) was more common in patients with Sjögren's syndrome and was associated with greater relief from treatment. Discomfort-based analysis showed strong correlations between ocular discomfort and subjective symptoms (ρ = 0.47, p < .001), but weak associations with clinical signs. Temporal analysis revealed 46% of patients had discordant symptom-sign trajectories over 9 months, while 54% demonstrated concordance. Concordance was highest for TBUT (47.5%) and lowest for Schirmer's test (32.7%). Antidepressant use was associated with concordance, while female sex and higher bodily pain scores were associated with symptom-dominant discordance. Symptom-sign discordance in DED is common, multifactorial, and persists over time. This is the first study to apply and compare 3 discordance classification methods in a single cohort. Each offers distinct clinical utility, allowing clinicians to better stratify DED patients and enabling more targeted treatment and referral strategies, thus improving outcomes.
Objectives: to evaluate the feasibility and utility of intraoperative optical coherence tomography (iOCT) utilizing an immersive augmented reality surgical headset (Beyeonics iOCT, Beyeonics Vision Ltd., Haifa, Israel) digital visualization platform with swept-source integrated OCT in ophthalmic surgery. Methods: As part of the Institutional Review Board-approved prospective DISCOVER study, the Beyeonics iOCT was utilized in multiple ophthalmic surgical procedures to evaluate the feasibility and utility of iOCT with this platform. The Beyeonics iOCT is a three-dimensional surgical visualization system that utilizes a swept-source integrated OCT within the digital microscope system. Surgeon feedback on system performance and integration into the surgical workflow was gathered via a prespecified survey. Results: Thirteen eyes of thirteen patients were included in this study. The surgical procedures consisted of four cataract surgeries, two lamellar corneal transplants, one pterygium removal, and six vitreoretinal surgeries. Surgeons were able to successfully view and review the iOCT images within the surgical Head-Mounted Display, eliminating the need for an external display. Utility feedback from surgeons included iOCT assisting with confirming wound architecture, corneal graft orientation, and retinal structure. All surgeries were completed without reverting to a conventional microscope, and no intraoperative adverse events occurred. Conclusions: The new visualization platform with integrated swept-source iOCT demonstrated feasibility and potential utility in multiple ophthalmic surgical platforms. Additional research related to outcomes, ergonomics, and enhanced software analysis is needed in the future.
Background/Objectives: To investigate the effect of ellipsoid zone (EZ) integrity and retinal fluid on best-corrected visual acuity (BCVA) in neovascular, age-related macular degeneration. Methods: This was a post hoc treatment-agnostic analysis of the phase 3 HAWK trial. Intraretinal fluid (IRF), subretinal fluid (SRF), and ellipsoid zone (EZ) integrity were quantified over 48 weeks. EZ integrity maintenance was defined as EZ-RPE central subfield thickness (CST) >20 µm; partial EZ attenuation was EZ-RPE CST >0 and ≤20 µm; total EZ attenuation was EZ-RPE CST = 0 µm. Results: During treatment, BCVA in eyes with no fluid (66.5 to 70.2 letters) was greater than in eyes with IRF (59.5 to 62.4 letters) but comparable to BCVA in eyes with SRF (64.9 to 68.8 letters). In eyes with no fluid, BCVA was consistently greater in eyes with EZ integrity maintained (73.4 to 78.4 letters) than in eyes with EZ partial attenuation (65.3 to 66.5 letters) or with EZ total attenuation (55.8 to 59.8 letters). Conclusions: Eyes without fluid with EZ preservation achieved the highest overall BCVA, especially when compared to eyes without fluid and a lack of EZ preservation and to eyes with SRF. Achieving a “dry” status with preservation of EZ integrity is important in optimizing visual outcomes.
Background/Objectives: Hydroxychloroquine (HCQ) retinopathy can be underrecognized early, as structural changes in OCT may precede symptoms and are often subtle. Early detection is crucial to prevent irreversible damage. This study evaluated longitudinal OCT changes preceding overt HCQ toxicity using ellipsoid zone (EZ) mapping. Methods: Patients on long-term HCQ underwent two macular cube scans at least one year apart using Cirrus HD-OCT. Scans were analyzed with an EZ-mapping platform and manually validated. Patients with baseline OCT signs of toxicity or co-existing macular disease were excluded based on masked expert review. Results: Three hundred and seventy-three eyes of 373 patients were included. The mean age was 57.0 ± 12.6 years, the mean HCQ dose was 379.4 ± 59.4 mg, the treatment duration was 5.6 ± 3.7 years, and the OCT interval was 3.1 ± 0.9 years. Outer retinal metrics remained stable across the cohort. The mean en face EZ attenuation increased from 3.3% to 3.9% (p = 0.24). Thirty-four eyes (9.1%) experienced an absolute increase of ≥4% (~1.5 mm2) in EZ attenuation. This increase was significantly associated with age at HCQ initiation (p < 0.001), age at the time of the first and second OCT (p < 0.001), and baseline visual acuity (p = 0.01), and demonstrated changes in other outer retinal metrics (p < 0.01). Only 3/34 eyes (8.9%) were diagnosed by the managing clinician with HCQ toxicity at the time of the second OCT. However, 26 of these eyes (76.5%) had signs of HCQ toxicity by expert review, suggesting the overall greater sensitivity of these quantitative outer retinal metrics for detecting toxicity compared with clinician review. Conclusions: Longitudinal OCT assessment revealed overall stability in outer retinal metrics in eyes on HCQ, but a subset showed increased EZ attenuation, which correlated with age at the time of HCQ initiation, baseline visual acuity, and expert OCT review. These changes may help identify at-risk eyes and eyes with early toxicity and warrant further validation as potential screening biomarkers.
Ellipsoid zone (EZ) integrity as measured by spectral-domain optical coherence tomography (SD-OCT) is a key biomarker and surrogate for photoreceptor health, including in age-related macular degeneration (AMD). The objectives of this study were to determine (1) the association of baseline EZ measures with geographic atrophy (GA) progression and photoreceptor loss, and (2) the impact of avacincaptad pegol (ACP), a complement inhibitor, on EZ integrity over the first year of treatment. Post hoc analysis of pooled data from the phase 2/3 GATHER1 and phase 3 GATHER2 trials. Patients ≥50 years of age with non‒center point involving GA in the study eye. SD-OCT images were evaluated using advanced multilayer segmentation with certified reader validation for EZ integrity, measuring total EZ attenuation or loss (EZ to retinal pigment epithelium [RPE] thickness of 0 μm; i.e., total loss of EZ) and partial EZ attenuation or degradation (EZ-RPE thickness of ≤20 μm). GA lesion growth was assessed through fundus autofluorescence. (1) Natural history assessment of progression of GA and total EZ attenuation in sham-treated eyes based on quartiles of baseline EZ measures, and (2) the impact of ACP treatment vs sham on progression of total and partial EZ attenuation over 12 months were evaluated. This study included 292 ACP 2 mg and 332 sham eyes. In sham-treated eyes, mean GA growth and progression of total EZ attenuation were substantially greater in higher quartiles of baseline total EZ attenuation and partial EZ attenuation measures over 12 months. ACP 2 mg significantly reduced mean growth in total EZ attenuation by 19.5% (P=0.0009) and mean growth in percentage of partial EZ attenuation by 55.3% (P<0.0001) vs sham over 12 months. Greater baseline total and partial EZ attenuation were associated with higher rates of GA lesion growth and progressive EZ loss over time, establishing these EZ measures as important predictors of future GA growth and photoreceptor loss. Treatment with ACP reduced EZ loss and degradation over 12 months vs sham. EZ measures may enhance identification of patients at high risk of disease progression who would benefit from early therapeutic intervention.